Abstract
RT-PCR methods have been developed, to date, by various groups to amplify the PML-RARA fusion gene produced by the t(15;17) in APL patients. However, these methods lack the necessary sensitivity to detect minimal residual disease (MRD) below the level of 1 leukaemic cell in 104 cells. Patients who test positive by these methods after treatment are likely to relapse. However, up to 25% of patients who test negative after treatment relapse within a short period. We have developed a 'hot-start' RT-PCR method for the amplification of PML-RARA with increased sensitivity at the level of two leukaemic cells in 106 cells. Using this method we were able to detect MRD in seven out of 15 patients tested in remission. Of the 11 patients in medium to long-term remission, five patients tested positive. None of these 11 patients tested positive with the standard RT-PCR. These results show that some patients in remission of APL continue to express PML-RARA even in long-term remission, when they can be considered clinically 'cured' of their disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tobal, K., Yin, J. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL. Leukemia 12, 1349–1354 (1998). https://doi.org/10.1038/sj.leu.2401133
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401133
Keywords
This article is cited by
-
Measurable residual disease testing in acute myeloid leukaemia
Leukemia (2017)
-
Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia
Rare Cancers and Therapy (2015)
-
Monitoring PML-RARα in acute promyelocytic leukemia
Current Oncology Reports (2003)
-
Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia
Leukemia (2002)
-
Detection and its clinical value of minimal residual diseases in acute promyelocytic leukemia
Chinese Journal of Cancer Research (2002)